Search the Newsreel

RYTM|Rhythm Pharmaceuticals Inc|Price:105.800|Chg%:-0.730

Rhythm Pharmaceuticals Inc (RYTM) has strong fundamentals, high growth potential, and is considered fairly valued within the pharmaceuticals industry. Institutional ownership is high, and analysts largely rate it as a "Buy" with an expected upward trend in the medium term. The company specializes in …

Precision Trading with Irhythm Technologies Inc. (IRTC) Risk Zones

This article provides a detailed analysis of Irhythm Technologies Inc. (IRTC) with a focus on risk zones for precision trading. It highlights a potential negative sentiment shift, weak broader alignment, and an exceptional short setup with a 55.8:1 risk-reward ratio targeting a 16.0% downside. …

RIME|Algorhythm Holdings Inc|Price:0.418|Chg%:+0.016

Algorhythm Holdings Inc (RIME) is an AI technology and consumer electronics holding company, with its primary business unit, SemiCab, focusing on AI-enabled logistics software. Despite healthy fundamentals and significant growth potential, the stock has shown very weak market performance over the past month. Analysts …

Algorhythm Holdings, Inc. Revenue Breakdown – NASDAQ:RIME

Algorhythm Holdings, Inc. (NASDAQ: RIME) generated $4.39 million USD in revenue last year, primarily from its SemiCab segment. This segment contributed the entire $4.39 million, a significant increase from $297,000 USD in the previous year. India was the primary revenue source, accounting for all …

Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (IRTC) breached their fiduciary duties to shareholders. The firm encourages long-term iRhythm shareholders to contact them to discuss potential legal rights and options, including corporate …

iRhythm Holdings (IRTC) Could Be 34% Undervalued Following Its Recent Rebound

Bronstein, Gewirtz & Grossman, LLC Encourages iRhythm Technologies, Inc. (IRTC) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against iRhythm Technologies, Inc. (IRTC) on behalf of investors who purchased securities before January 11, 2022, and still hold them. The investigation aims to determine if iRhythm and its officers engaged in corporate wrongdoing. Shareholders …

Law firm investigates iRhythm officers over alleged stock price inflation via product misrepresentation

Kuehn Law, PLLC is investigating officers and directors of iRhythm Technologies for allegedly breaching fiduciary duties by misrepresenting their Zio AT monitor. The firm claims insiders falsely promoted the product's market potential, leading to artificially inflated stock prices. Investors who purchased shares before November …

Could Anticipated Q2 Earnings Beat Amid Weaker Profitability Reframe Rhythm Pharmaceuticals’ Growth Story (RYTM)?

In early August 2026, Rhythm Pharmaceuticals is scheduled to report quarterly results that analysts expect will show higher revenue but a year-over-year earnings decline, with many anticipating a potential earnings beat versus consensus estimates. This combination of rising sales and the prospect of outperforming …

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Rhythm Pharmaceuticals, Inc. (RYTM) is predicted to surpass Q2 earnings estimates, despite an expected year-over-year decline in earnings but higher revenues. The company's Zacks Earnings ESP of +1.46% combined with a Zacks Rank #3 suggests a strong probability of an earnings beat. Investors will …

Rhythm Pharmaceuticals (RYTM) Projected to Announce Earnings on Tuesday

Rhythm Pharmaceuticals Inc (RYTM) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Rhythm Pharmaceuticals Inc (RYTM), highlighting its current valuation score of 9.55, which ranks 16th in the Pharmaceuticals industry. The P/E ratio is noted as -33.84, with other key metrics like P/B, P/S, and P/CF not yet disclosed …

IRTC|iRhythm Technologies Inc|Price:112.260|Chg%:+3.060

This article provides a comprehensive stock analysis of iRhythm Technologies Inc (IRTC), highlighting its strong fundamentals, high growth potential, and fair valuation. The company's stock is rated a "Strong Buy" by multiple analysts with a target price of $178.00, indicating a significant upside. Key …

Algorhythm Holdings Inc (RIME) Financial Health: Profitability & Balance Sheet Analysis

Algorhythm Holdings Inc (RIME) holds a financial score of 5.73, ranking 31st out of 34 in its industry, indicating stable financial health but low operating efficiency. The company recently reported a 20.42% year-over-year increase in quarterly revenue to $2.40M and a 44.45% increase in …

Rhythm Pharmaceuticals Inc (RYTM) Cash Flow

This article provides a detailed historical cash flow statement for Rhythm Pharmaceuticals Inc (RYTM), displaying data quarterly and annually across several fiscal years. It includes operational, investing, and financing cash flow metrics, along with explanations of these financial terms and their significance. The data …

Algorhythm Holdings Inc (RIME) Income Statement

This article provides the quarterly and annual income statement data for Algorhythm Holdings Inc (RIME), offering insights into the company's financial performance and operational efficiency. It details various financial metrics including total revenue, cost of revenue, operating expenses, operating profit, income before tax, and …

Form DEF 14A Algorhythm Holdings Inc For: 27 July By Investing.com

This article announces the filing of Form DEF 14A by Algorhythm Holdings Inc. for July 27. It provides a brief mention of the filing without further details on its content or implications. The article appears within a financial news platform that also lists various …

Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against iRhythm Technologies, Inc. (IRTC) for alleged corporate wrongdoing. The firm encourages shareholders who purchased iRhythm securities before January 11, 2022, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates …

JPMorgan initiates Rhythm Pharmaceuticals stock at Overweight

JPMorgan initiated coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with an Overweight rating and a $145.00 price target, citing the company's potential to expand its Imcivree drug franchise. The firm believes Imcivree's recent expansion into acquired hypothalamic obesity and future indications like congenital hypothalamic obesity and …

Rhythm Pharmaceuticals Inc (RYTM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey

This article provides a brief overview of Rhythm Pharmaceuticals Inc (RYTM), highlighting its current stock price, market capitalization, and regional revenue breakdown. The company's revenue distribution shows significant contributions from both the United States and International markets. Financial data for specific business segments and …

Rhythm Pharmaceuticals (RYTM) Faces A Big Undervaluation Call, Is The Upside Already Priced In?

Rhythm Pharmaceuticals (RYTM) has captured investor interest due to a narrative suggesting it is 26.8% undervalued, with a fair value of $139.47 per share, significantly higher than its current $102.10. This valuation is heavily based on anticipated revenue growth from its drug setmelanotide and …

Rhythm Pharmaceuticals, Inc. $RYTM Shares Acquired by Orbimed Advisors LLC

Sona Asset Management US LLC Invests $1.54 Million in Pyrophyte Acquisition Corp. II $PAII

Rhythm Pharmaceuticals, Inc. $RYTM Shares Bought by SummitTX Capital L.P.

Algorhythm Settles Liabilities Through Equity Issuance Agreement

Algorhythm Holdings (RIME) has settled approximately $1.93 million in liabilities by issuing up to 5 million shares of common stock to Continuation Capital, Inc. The settlement, approved by a Florida court, aims to reduce debt but may dilute equity holders. Additionally, the company amended …

RIME|Algorhythm Holdings Inc|Price:0.446|Chg%:-0.018

TradingKey provides a comprehensive stock analysis for Algorhythm Holdings Inc (RIME), noting its healthy fundamentals, significant growth potential, and high institutional ownership. The company, an AI technology and consumer electronics holding company, is considered fairly valued and has received a "Buy" rating from analysts …

Rhythm Pharmaceuticals (RYTM) Q1 2023 Earnings Report - Results, Call & Slides

Rhythm Pharmaceuticals (RYTM) released its Q1 2023 earnings report, missing both EPS and revenue expectations. The company reported an actual EPS of -$16.11 against a consensus of -$12.57, and actual revenue of $200.81M compared to an expected $212.19M, although showing significant year-over-year revenue growth …

PAII|Pyrophyte Acquisition Corp II|Price:10.235|Chg%:+0.005

This article provides a detailed financial overview of Pyrophyte Acquisition Corp II (PAII), a blank check company. It includes current stock price, market capitalization, key financial figures, technical indicator analysis, and major shareholders. The company has not yet disclosed EPS or total revenue data, …

PAII|Pyrophyte Acquisition Corp II|Price:10.240|Chg%:-0.010

This article provides a detailed financial overview of Pyrophyte Acquisition Corp II (PAII), a blank check company. It includes current stock price, market capitalization, key financial figures, technical indicator analysis, and major shareholders. The company has not yet disclosed EPS or total revenue data, …

iRhythm Technologies Inc (IRTC) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for iRhythm Technologies Inc (IRTC). It notes that no dividends have been distributed by IRTC over the past five years. The page displays the current stock price, market cap, and links to various …

Algorhythm Holdings Inc (RIME) Earnings Date & Reports & Earnings News

Rhythm Pharmaceuticals, Inc. Revenue Breakdown – FWB:1RV

Rhythm Pharmaceuticals, Inc. (FWB:1RV) generated €165.83 million in revenue last year, with its Therapeutics segment being the top performer, contributing €161.56 million. The United States was the largest geographical contributor, accounting for €113.71 million of the revenue. This data highlights the company's key revenue …

Algorhythm Holdings Inc (RIME) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Algorhythm Holdings Inc (RIME), providing a breakdown of major shareholders and institutional holdings. It lists key shareholders like Streeterville Capital LLC and Jane Street Capital, L.L.C., along with their respective proportions. The report also includes quarterly data …

Algorhythm Holdings (NASDAQ: RIME) may issue 5,000,000 shares to settle claim

Algorhythm Holdings, Inc. (NASDAQ: RIME) has reached a settlement agreement with Continuation Capital, Inc. to resolve a $1,928,014 claim. Under the agreement, Algorhythm may issue up to 5,000,000 shares of common stock in tranches until Continuation Capital receives 120% of the claim amount, with …

Algorhythm amends employment agreements with CEO Gary Atkinson and CFO Alex Andre

Algorhythm entered into amended and restated employment agreements with CEO Gary Atkinson and CFO & General Counsel Alex Andre, effective July 22, 2026. These amendments aim to harmonize change-of-control treatment and incorporate new bonus and tax-compliance provisions for both executives. The new agreements supersede …

Algorhythm Holdings Strikes Section 3(a)(10) Settlement; Up to 5M Shares to Retire $1.93M Debt

Algorhythm Holdings has entered into a Section 3(a)(10) settlement with Continuation Capital to resolve $1,928,014 in liabilities. The company may issue up to 5,000,000 common shares in tranches to Continuation Capital, subject to a 19.99% ownership cap, until 120% of the claim amount is …